colon cancer

The study reports the anticancer activity of the methanolic extract of Eclipta alba on two human colon cancer cell lines, namely HCT-116 and HT-29. In simple terms, the objectives of the research include the cytotoxic efficacy of the extract, its capability to inhibit cellular migration, and its importance in colony formation. The extract showed significant cytotoxic effects on its subordinates with IC₅₀ values ranging between 200 to 400 μg/mL in an array of assays used, such as MTT, wound healing, and clonogenic assays. There is impressive selectivity toxicity since it can spare the normal fibroblast cells-WI-38. This is a proof that it can be especially defined as an anticancer drug. Furthermore, the results have established that the extract has the ability to inhibit cancer cell migration and colony formation; therefore, it can functionally represent such a potential for the very crucial cancer treatment and prevention of metastasis. These observations are consistent with the previous study, and this fosters the vision that Eclipta alba is a potentially useful drug from nature as a natural medicinal drug. For further studies, its application should be developed for cancer therapy with research based on its bioactive combinations, subatomic components, and in vivo adequacy.